Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Dechra shares Osphos trial data at BEVA Congress

Dechra shares Osphos trial data at BEVA Congress

6th October 2014

Dechra has shared new clinical trial data on the efficacy of its Osphos treatment, an intramuscular clodronic acid injection designed to combat lameness in horses, at the British Equine Veterinary Association (BEVA) Congress 2014.

Osphos is the only UK-licensed veterinary product for the control of clinical signs linked to bone resorptive processes in animals with navicular syndrome.

According to Dechra's new data, it is well-tolerated and effective, with almost three-quarters (74.7 per cent) of subjects in the recent trial showing an improvement of at least one lameness grade within 56 days of initial administration.

Emma Jennings, equine brand manager for the company, commented: "The trial proved that Osphos is effective at 6 months post-treatment."

An injection of clodronic acid helps to mitigate the effects of navicular syndrome in horses by inhibiting resorption in the navicular bone, binding to hydroxyapatite crystals and exercising direct cellular effects on osteoclasts.ADNFCR-8000103-ID-801752729-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.